Arvinas Shares Dive on Trial Results for Metastatic Breast Cancer Treatment
Arvinas shares dived 40% following results from a Phase 3 clinical trial evaluating vepdegestrant as a treatment for a type of metastatic breast cancer. Shares were trading around $10.35. The stock is down 61% over the last year.
Pfizer's Covid-19 vaccine is considered by healthcare authorities to be safe and effective, with data gathered from billions ...
Five years after the start of the pandemic, the fight over who owns the underlying technologies that made the Covid-19 ...
Pfizer's strong fundamentals, impressive R&D achievements, and undervalued metrics underscore its defensive appeal and growth ...
Representative Jefferson Shreve (R-Indiana) recently bought shares of Pfizer Inc. (NYSE:PFE). In a filing disclosed on March ...
An alternative to Paxlovid, the only antiviral pills approved by the US Food and Drug Administration to treat COVID-19, is on ...
Pfizer on Thursday named James List as the head of the drugmaker's Internal Medicine portfolio, where he will oversee the ...
"I was expecting him probably to win. It was very big win," Pfizer's CEO Albert Bourla said of President Donald Trump's ...
VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant and clinically ...
Trial results show vepdegestrant, a protein-degrading drug Arvinas is developing with Pfizer, improved on fulvestrant in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback